Author:
Oso Babatunde Joseph,Oyewo Emmanuel Bukoye,Oladiji Adenike Temidayo
Abstract
Abstract
Background
Tumour necrosis factor ligand superfamily member 8 (TNFL8) is a cytokine that plays vital roles in immune activations and inflammatory responses through its interaction with the tumour necrosis factor superfamily member. Despite multiple studies on the involvement of its receptor in the inflammatory response, there is limited information on the molecular characterization and structural elucidation of the cytokine. Considering the significance of the cytokine, the three-dimensional structure of TNFL8 model was generated by homology modelling through the Iterative Threading ASSEmbly Refinement (I-TASSER) server and validated through PROCHECK and Qualitative Model Energy Analysis (QMEAN) servers.
Results
The predicted structure has 90.00% of residues in the most favoured region of the Ramachandran plot while the QMEAN value gives − 3.06. The sequence and structural alignment between the generated model of the cytokine and template (1XU2) reveal that similar active site residues such as ILE-142, THR-175, GLU-178, and PHE-228 could be involved in binding pocket formation. However, docking studies of the 3D model of TNFL8 with eight phytochemicals from the extract of Xylopia aethiopica (Dunal) A. Rich revealed the phytochemical bound to two different binding sites which could be the active regions of the cytokine that could be essential for inhibition. More so, the docking analysis showed most of the phytochemicals have good binding affinity to the cytokine with ellagic acid showing the highest affinity with a binding energy of − 6.58 ± 0.18 kcal/mol.
Conclusion
The proposed model may shed light on the mechanisms of TNFL8 binding and provide insights into the identification of potential molecular targets for the development of the novel compound for the regulation of the functional activities of the cytokine.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Wiley SR, Goodwin RG, Smith CA (1996) Reverse signaling via CD30 ligand. J Immunol 157(8):3635–3639
2. Nielson C, Fischer R, Fraga G, Aires D (2016) Loss of CD30 expression in anaplastic largecell lymphoma following brentuximab therapy. J Drugs Dermatol 15(7):894–895
3. Gottesman SR (2016) CD30: receptor, marker, target. Path Lab Med Int 8:27–36
4. Lee SY, Lee SY, Kandala G, Liou ML, Liou HC, Choi Y (1996) CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci USA 93(18):9699–9703. https://doi.org/10.1073/pnas.93.18.9699
5. Shi JH, Sun SC (2018) Tumor necrosis factor receptor-associated factor regulation of nuclear factor κB and mitogen-activated protein kinase pathways. Front Immunol 9:1849. https://doi.org/10.3389/fimmu.2018.01849